Research Analysts’ updated eps estimates for Tuesday, September 5th:

Ambarella (NASDAQ:AMBA) had its target price cut by Canaccord Genuity from $72.00 to $58.00. Canaccord Genuity currently has a buy rating on the stock.

Ares Management L.P. (NYSE:ARES) had its buy rating reaffirmed by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a $22.00 price target on the stock.

Rockwell Collins (NYSE:COL) had its neutral rating reiterated by analysts at Buckingham Research.

Rockwell Collins (NYSE:COL) had its hold rating reissued by analysts at Vertical Research.

Costco Wholesale Corporation (NASDAQ:COST) had its hold rating reiterated by analysts at Deutsche Bank AG. Deutsche Bank AG currently has a $172.00 target price on the stock.

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its buy rating reiterated by analysts at SunTrust Banks, Inc.. They currently have a $5.00 price target on the stock.

Walt Disney Company (The) (NYSE:DIS) had its buy rating reiterated by analysts at Guggenheim. Guggenheim currently has a $122.00 target price on the stock.

easyJet plc (LON:EZJ) was given a GBX 1,465 ($18.92) target price by analysts at UBS AG. The firm currently has a buy rating on the stock.

Freeport-McMoran (NYSE:FCX) had its sell rating reiterated by analysts at Berenberg Bank. The firm currently has a $10.40 price target on the stock.

Fitbit (NYSE:FIT) had its neutral rating reaffirmed by analysts at Robert W. Baird. The firm currently has a $6.00 price target on the stock.

Fraport AG Frankfurt Arprt Svcs Wrldwde (FRA:FRA) was given a €62.00 ($73.81) price target by analysts at UBS AG. The firm currently has a sell rating on the stock.

International Consolidated Airlns Grp SA (LON:IAG) was given a GBX 685 ($8.85) target price by analysts at UBS AG. The firm currently has a buy rating on the stock.

Intuitive Surgical (NASDAQ:ISRG) had its overweight rating reaffirmed by analysts at Morgan Stanley. They currently have a $1,150.00 target price on the stock, up from their previous target price of $1,070.00.

Kroger Company (The) (NYSE:KR) had its buy rating reissued by analysts at Deutsche Bank AG. They currently have a $26.00 price target on the stock.

Deutsche Lufthansa AG (ETR:LHA) was given a €20.75 ($24.70) target price by analysts at UBS AG. The firm currently has a neutral rating on the stock.

OM Asset Management PLC (NYSE:OMAM) had its buy rating reaffirmed by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a $17.50 price target on the stock.

Omnicell (NASDAQ:OMCL) had its price target increased by Benchmark Co. from $55.00 to $67.00. Benchmark Co. currently has a buy rating on the stock.

Och-Ziff Capital Management Group (NYSE:OZM) had its hold rating reiterated by analysts at Keefe, Bruyette & Woods. The firm currently has a $3.25 price target on the stock.

Palo Alto Networks (NYSE:PANW) had its buy rating reissued by analysts at Dougherty & Co. They currently have a $165.00 price target on the stock, up from their previous price target of $155.00.

Palo Alto Networks (NYSE:PANW) had its buy rating reaffirmed by analysts at Stifel Nicolaus. The firm currently has a $180.00 target price on the stock.

Palo Alto Networks (NYSE:PANW) had its market perform rating reaffirmed by analysts at William Blair.

Palo Alto Networks (NYSE:PANW) had its sector perform rating reissued by analysts at FBN Securities. The firm currently has a $155.00 price target on the stock, up from their previous price target of $135.00.

Progenics Pharmaceuticals (NASDAQ:PGNX) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. The firm currently has a $15.00 price target on the stock.

Koninklijke Philips NV (AMS:PHIA) was given a €36.00 ($42.86) target price by analysts at Citigroup Inc.. The firm currently has a buy rating on the stock.

Ralph Lauren Corporation (NYSE:RL) had its price target boosted by Macquarie from $96.00 to $100.00. They currently have an outperform rating on the stock.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) had its neutral rating reaffirmed by analysts at Cantor Fitzgerald. The firm currently has a $27.00 target price on the stock.

Vmware (NYSE:VMW) had its target price boosted by Oppenheimer Holdings, Inc. from $110.00 to $120.00.

Workday (NYSE:WDAY) had its neutral rating reaffirmed by analysts at Credit Suisse Group. The firm currently has a $100.00 price target on the stock, up from their previous price target of $94.00.

Acceleron Pharma (NASDAQ:XLRN) had its hold rating reissued by analysts at Cann. The analysts wrote, “Acceleron Pharma announced today that The Lancet Oncology has published results from the phase II study of Luspatercept in patients with lower-risk myelodysplastic syndromes (MDS). Acceleron reported that the article, entitled Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2 dose-finding study with long-term extension study” is now available online and will be published in a future print issue of The Lancet Oncology. The journal also published online a companion Comment article, Defeating anaemia in myelodysplastic syndromes: another step forward,” by Valeria Santini, M.D., Associate Professor of Hematology at the University of Florence Medical School in Florence, Italy.””